Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(62)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 M{PKU2N6fG:2b4jpZ{BCe3OjeR?= MYqxNEBvVQ>? MYC3NkBp Mn;nSG1UVw>? MXvQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= NWHmcWJ4OjR7MEC4O|M>
HT-29 NUXvfIZoS3m2b4TvfIlkKEG|c3H5 NEjvcYYyOCCwTR?= NFXhTmM4OiCq NFnyS5ZFVVOR NGjKenBRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= M4DweVI1QTByOEez
HT-29 NV\uUHB[S3m2b4TvfIlkKEG|c3H5 MYCxNEBvVQ>? MkXMO|IhcA>? NH30O2lFVVOR NI\wW3JRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MlvjNlQ6ODB6N{O=
PC3 M32yRmtqdmG|ZTDBd5NigQ>? NX\1UZkzOTByIH7N M{HZcFEhcA>? MoHjSG1UVw>? M4TINnBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u MlKzNlE6Pzh4OEO=
PC3 MYPLbY5ie2ViQYPzZZk> NUjzVHo2OTByIH7N NUTkdYVyOSCq NXjoNJh4TE2VTx?= NV3C[INRTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= M3\DSlIyQTd6Nkiz
PC3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\VcG0yNjVizszN NFPzTYwyKGh? Ml7wSG1UVw>? M2HCWGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NVrmb|FwOjF7N{i2PFM>
HEK293 M2jFfmZ2dmO2aX;uJGF{e2G7 MVKxNFAhdk1? MnvaPEBp NVHzPWtLTE2VTx?= M37tZmlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= NXfodIFIOjF3M{mzNFE>
BT-20 MmL3T4lv[XOnIFHzd4F6 NWWzcm5jOjBizszN NYrMcWJPTE2VTx?= NHrScmhFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= MlvwNlE{PTN3NUG=
U937 NVq0WIRiSW62aXLhZ5RmemmjbDDBd5NigQ>? Mn\2OVAh|ryP MlOyOFghcA>? MknsSG1UVw>? NEPJfVNKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= M3fVWlIyOTR{MUC2
U937 NUjac4t4SW62aXLhZ5RmemmjbDDBd5NigQ>? MlfiOVAh|ryP MnfWOFghcA>? MX7EUXNQ NIHzXYtFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| M1vmc|IyOTR{MUC2
U937 NF;YeXRCdnSrYnHjeIVzcWGuIFHzd4F6 MWO1NEDPxE1? NYDae3lXPDhiaB?= NIrSZmJFVVOR MX3Ec4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> MWKyNVE1OjFyNh?=
MCF-7 NGjLXlVCfXSxcHjh[5khSXO|YYm= NIT0OGI{OCCwTR?= NGPySWs1KGh? Mn;tSG1UVw>? Mnr4TY5lfWOnczDheZRweGijZ4m= NYnZdYFFOjByMkixN|Q>
U87MG M2\ke2tqdmG|ZTDBd5NigQ>? NYLCVW5yOSEQvF2= M{fwXFYhcA>? MnW2SG1UVw>? MVLQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? NEH2SFcyQTh2OESwOC=>
U87MG MV7LbY5ie2ViQYPzZZk> NUHodplDOSEQvF2= M1fxT|YhcA>? M3TJcGROW09? NYTOU5p[WG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> NGrBR4UyQTh2OESwOC=>
U87MG M2P1N2tqdmG|ZTDBd5NigQ>? NIHnZlQyKM7:TR?= M3rRUVYhcA>? M1nNS2ROW09? MmXuSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NUWze4NtOTl6NEi0NFQ>
U87MG MkXzT4lv[XOnIFHzd4F6 NUX1ZVZjOSEQvF2= Mly1OkBp MmLISG1UVw>? MYPEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NWPpZXhzOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb NVviVWVoSXW2b4DoZYd6KEG|c3H5 NYKwSGdFOC5{IN88US=> NXfKV4ZQOjRiaB?= NF\UbphFVVOR M1ixZWlv\HWlZYOgZZV1d3CqYXf5 M4TSc|E5OzlzOUS5
COS7 cells expressing EGFP-LC3 M163UWF2fG:yaHHnfUBCe3OjeR?= NEnzUmwxNjJizszN M33nWFI1KGh? MUHEUXNQ NULHPHlFUW6mdXPld{BifXSxcHjh[5k> NX:wTnJjOTh|OUG5OFk>
H4 NYTyb2JtTnWwY4Tpc44hSXO|YYm= NXnsR4pSOC5{IN88US=> NGXETlUzPCCq MoixSG1UVw>? M{f6bWlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> M3LCc|E5ODJ2NUi0
HeLa MVnGeY5kfGmxbjDBd5NigQ>? M2rTXVExOCCwTR?= MX:zOkBp NXf1OYtWTE2VTx?= NI\PTWJKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NEjlSmcyPzV4M{O4OS=>
HeLa NVzPZ|NoTnWwY4Tpc44hSXO|YYm= M3vS[|ExOCCwTR?= NVjsT2ljOzZiaB?= M2TVe2ROW09? MmXuTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MkHxNVc2PjN|OEW=
HeLa NX\P[nh5TnWwY4Tpc44hSXO|YYm= NV7QSVE6OTByIH7N Ml\HN|YhcA>? M13hPWROW09? NHnRO5ZKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NILjWIIyPzV4M{O4OS=>
SYF NED2doRHfW6ldHnvckBCe3OjeR?= NHvzPJkyODBibl2= NWfuc5l2OjRiaB?= MnuwSG1UVw>? NGD5OWNKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> M1rVXlE4PTZ|M{i1
SYF NVe2Xmg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TRVFExOCCwTR?= NVztVnQ4OjRiaB?= NVnm[mMyTE2VTx?= M2DCdWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= NIj5OW8yPzV4M{O4OS=>
HEK293T MXjBcpRqfmm{YXygRZN{[Xl? M3u0RlEhdk1? NYX5WHFVPCCm NIX3dZZFVVOR NGLHR3VKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> M2jO[FE4PDh3NUCx
HEK293T NUnyWIhOSW62aY\pdoFtKEG|c3H5 NIC4PHoyKG6P NXy5PJNZPCCm Mo\ZSG1UVw>? M{ntUmlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N NU\oc3JCOTd2OEW1NFE>
PBMC MkjrSpVv[3Srb36gRZN{[Xl? NYrhT3M{OSCwTR?= NVX6eW9mOTRiZB?= MYnEUXNQ M4PtT3Jm\HWlZYOgR2NTPSCmZX7zbZR6 NFPHfVUyPzR6NUWwNS=>
PBMC NHu0No9HfW6ldHnvckBCe3OjeR?= NHzGS5EyKG6P MVmxOEBl M1rWcWROW09? NHOwZWVFd2W|IH7veEBi\m[nY4SgR3hEWjRiZHXud4l1gQ>? NIezPZcyPzR6NUWwNS=>
HEK293 cells M{HKTGtqdmG|ZTDBd5NigQ>? NVzPVFU4PTBibl2= MkHEOFUhdWmw M1zBeWROW09? NWPYO5RiUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= M2LMPVE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NEjlS2RHfW6ldHnvckBCe3OjeR?= NUf5d4g2OTByIH7N NXPXR4ZTPCCq MWrEUXNQ MX7JcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> MX2xO|EzQDJ4Mh?=
Human mixed lymphocyte MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUe1JI5O MYnEUXNQ MmjPTWM2OD1zLk[gcm0v MkCyNVYyQDV6NkW=
Lewis rat lymph node cells NUS1WVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX21JO69VQ>? MkTRSG1UVw>? Ml62TWM2OD1{Lk[g{txO NFrlUpMyPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNEBvVQ>? NX\6XW9[PzJiaB?= NYjVSVhmTE2VTx?= M1PJWWlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= M1;5VFExODJzOUS4
MRK-nu-1 MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3DZ29KSzVyPUCuPFQ2KHCP MlzPV2FPT0WU
OCUB-M M{\WUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnqUFFKSzVyPUWuNlQheE1? M4jEN3NCVkeHUh?=
SF539 M3HoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fQNWlEPTB;MUGuOkBxVQ>? NXzWR3RtW0GQR1XS
ES4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrzTWM2OD1{MT61JJBO NH;ORXlUSU6JRWK=
RL95-2 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTVVlJPUUN3ME2xNFcheE1? NHzjbVFUSU6JRWK=
LC-2-ad NVnlOmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTR{MzDwUS=> NXXnflVOW0GQR1XS
Daudi M3XGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTNTWM2OD12M{SgdG0> MmTUV2FPT0WU
NTERA-S-cl-D1 NYXIWHpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInPUoRKSzVyPUS0N{BxVQ>? MVfTRW5ITVJ?
OS-RC-2 NGi1UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j3WGlEPTB;NkWyJJBO NXr6d4dmW0GQR1XS
VA-ES-BJ NFHaSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LDd2lEPTB;N{KzJJBO NILnbZpUSU6JRWK=
GR-ST M13FN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTh2NjDwUS=> NIH5XHdUSU6JRWK=
SW872 NWf4N4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzBUo1KSzVyPUi0OkBxVQ>? M1PiZ3NCVkeHUh?=
NOS-1 M2fDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zQNWlEPTB;OEexJJBO MVrTRW5ITVJ?
MC116 NITJZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLWTWM2OD17OEWgdG0> NG[1XXpUSU6JRWK=
NCI-H1355 M4DGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFwMEGgcm0> NWXnRpVSW0GQR1XS
RPMI-8226 NUXaUHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H5bWlEPTB;MT6xPUBvVQ>? M1r3[HNCVkeHUh?=
TE-15 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwM{[gcm0> M3roUHNCVkeHUh?=
Ramos-2G6-4C10 M3rGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP0N|huUUN3ME2xMlQ3KG6P MoXBV2FPT0WU
KU812 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLMTWM2OD1{LkCxJI5O M2Do[nNCVkeHUh?=
EW-1 NEnBcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\ZXnVKSzVyPUKuNVchdk1? NXO3cplUW0GQR1XS
KS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[3[GlEPTB;Mj60OUBvVQ>? MX;TRW5ITVJ?
SK-LMS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfmSJRKSzVyPUKuOFkhdk1? MVTTRW5ITVJ?
TGBC1TKB M4\YW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPEO2RKSzVyPUKuOlkhdk1? MkTNV2FPT0WU
TE-6 NILq[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\Q[GlEPTB;Mj63O{BvVQ>? NEfoT25USU6JRWK=
ETK-1 MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq0NJZKSzVyPUKuPFIhdk1? NHr4PYZUSU6JRWK=
BE-13 NUPHOYEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJwOUmgcm0> NXS4VHdtW0GQR1XS
A3-KAW NHTLOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDKTWM2OD1{Lkm5JI5O MYLTRW5ITVJ?
TE-10 NHviN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\uXoZKSzVyPUOuN{BvVQ>? MWnTRW5ITVJ?
DOHH-2 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHzPZJKSzVyPUOuN|Uhdk1? NY\QN2s{W0GQR1XS
ES6 NWP2dI5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTNwNEOgcm0> NF7o[5RUSU6JRWK=
OPM-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTRwMUWgcm0> NH3OPW5USU6JRWK=
SH-4 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7leJJKSzVyPUSuN|Qhdk1? NG\ZRnZUSU6JRWK=
NB13 M3rtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u2[GlEPTB;ND6zOkBvVQ>? MmXwV2FPT0WU
HUTU-80 NVGwOo1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPzdoYyUUN3ME20MlQzKG6P NEm2UHdUSU6JRWK=
CCRF-CEM NX[1XJFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTRwOUSgcm0> NGDtR29USU6JRWK=
TGBC24TKB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljuTWM2OD13LkWxJI5O NGW5N5VUSU6JRWK=
697 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[xTWM2OD14LkK4JI5O NEHnVohUSU6JRWK=
J-RT3-T3-5 NUi3WHFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\tTWM2OD14LkS2JI5O NGX6flFUSU6JRWK=
KALS-1 M4fleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZwNU[gcm0> NFrmblRUSU6JRWK=
no-10 NXvFZmhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTdwMkmgcm0> NF33eG1USU6JRWK=
SK-NEP-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnETWM2OD16Lke5JI5O M3n4RXNCVkeHUh?=
L-540 NE\1cnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rpSmlEPTB;MUCuOFIhdk1? NHq4O21USU6JRWK=
JiyoyeP-2003 MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnK[WVKSzVyPUGwMlk1KG6P NV2wXXpzW0GQR1XS
HH NWnHNZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fRTWlEPTB;MUGuN|khdk1? NIjW[2RUSU6JRWK=
SR NVm0PWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFzLkS1JI5O MVrTRW5ITVJ?
QIMR-WIL NILDO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLuSGNKUUN3ME2xNU45PSCwTR?= MkK0V2FPT0WU
A4-Fuk MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILNVZZKSzVyPUGzMlEzKG6P M{LvbXNCVkeHUh?=
CESS NHjrUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF|LkGzJI5O NWjhPVlwW0GQR1XS
KE-37 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF4LkC3JI5O Mlj5V2FPT0WU
SK-UT-1 NWL0cJlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DGTGlEPTB;MU[uPFEhdk1? M4DE[XNCVkeHUh?=
SIG-M5 NETJfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq1TWM2OD1zNz6yOUBvVQ>? MWTTRW5ITVJ?
HT MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLkTWM2OD1zNz62JI5O M4DLUnNCVkeHUh?=
DEL NGT6bJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6xbVZzUUN3ME2xO{46QSCwTR?= NFmwNHNUSU6JRWK=
SK-PN-DW MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULVR2ZFUUN3ME2yNE4zOyCwTR?= NVriNFVtW0GQR1XS
RPMI-8402 NYi2Z3dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TmemlEPTB;MkGuO|chdk1? NH32NphUSU6JRWK=
RPMI-6666 NWTXW|lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXu[GJKSzVyPUK0MlQzKG6P NGDNdFNUSU6JRWK=
NCI-H720 M{KxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfmTWM2OD1{NT60NUBvVQ>? MkTJV2FPT0WU
EW-16 NFLlOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfGfXlyUUN3ME2yOk45PyCwTR?= NHrKW41USU6JRWK=
BL-70 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jGUGlEPTB;MkiuN|ghdk1? NEOwfYxUSU6JRWK=
SF126 NEP4VHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHCTWM2OD1|MD6zPEBvVQ>? MnnwV2FPT0WU
BC-1 NYnudZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\we3hKSzVyPUOxMlI3KG6P M{LNNHNCVkeHUh?=
MHH-PREB-1 NULVdVZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\WOYJPUUN3ME2zNk41PCCwTR?= M3H6RnNCVkeHUh?=
A101D M1LtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3uNm5qUUN3ME2zNk43OiCwTR?= MXzTRW5ITVJ?
NMC-G1 M3fCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rkV2lEPTB;M{OuOlchdk1? NUntU4VbW0GQR1XS
LB1047-RCC MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:1eFNKSzVyPUO0MlY6KG6P NW\Nfm5QW0GQR1XS
EM-2 M2ru[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HteGlEPTB;M{iuOVMhdk1? NF;Gbo1USU6JRWK=
COLO-684 NGPl[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN7Lkigcm0> NVy1Umd{W0GQR1XS
Becker NF;5RlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvtbm1IUUN3ME20NU4xPSCwTR?= MoXJV2FPT0WU
BL-41 NWixcXBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvQTWM2OD12Mz62OkBvVQ>? NU\0WJNyW0GQR1XS
MDA-MB-134-VI MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTK[Vl3UUN3ME20OE4xOiCwTR?= MnzaV2FPT0WU
L-363 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT4U5pKUUN3ME20OE44OyCwTR?= MXnTRW5ITVJ?
ECC4 M3;6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR2Lke4JI5O M{DWSnNCVkeHUh?=
A388 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTR2LkiyJI5O NVraXlFQW0GQR1XS
HEL NFTmcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zMe2lEPTB;NEmuO|khdk1? NHHNc3hUSU6JRWK=
RKO NH7KU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr6c2xKSzVyPUWwMlI6KG6P NUTX[Gl7W0GQR1XS
KINGS-1 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LoO2lEPTB;NUGuOVUhdk1? MXLTRW5ITVJ?
EB-3 M3TGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\qTmlEPTB;NUKuOlchdk1? NHq1[nNUSU6JRWK=
ARH-77 M3LpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTV{Lkigcm0> MofMV2FPT0WU
GCIY MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDQTWM2OD13Mz60OkBvVQ>? M3vYT3NCVkeHUh?=
NCI-H1304 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTV5LkKyJI5O NF;RT3dUSU6JRWK=
KARPAS-299 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zucGlEPTB;NkGuPFIhdk1? M3nE[3NCVkeHUh?=
IA-LM NYflZllZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofpTWM2OD14OD6xN{BvVQ>? NXT5ZVZjW0GQR1XS
GI-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTdyLkO5JI5O NYfIXZM1W0GQR1XS
TE-11 MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv4TIFKSzVyPUe3MlE4KG6P Ml\MV2FPT0WU
LS-411N NX;TUmw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTd5LkW3JI5O MnuzV2FPT0WU
no-11 M4jp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT0NnZpUUN3ME24N{4zPCCwTR?= MVjTRW5ITVJ?
MV-4-11 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECwVpBKSzVyPUizMlc{KG6P NY\LZVlvW0GQR1XS
BV-173 NULzbWF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jXTGlEPTB;OEOuPVchdk1? Mlv3V2FPT0WU
CMK MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTh2LkG2JI5O M4rkR3NCVkeHUh?=
LC4-1 NYL5O5h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlftTWM2OD16Nj63NkBvVQ>? M{TQfnNCVkeHUh?=
COR-L279 M2jtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTh5LkK1JI5O MlnRV2FPT0WU
NCI-H209 NWDvcVR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn2TWM2OD16Nz60NUBvVQ>? M4HmN3NCVkeHUh?=
Raji MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTh7LkeyJI5O NYTk[5NEW0GQR1XS
LB996-RCC M4\mZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTWPIFkUUN3ME25N{41OyCwTR?= MVLTRW5ITVJ?
NCI-H526 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTl|LkW5JI5O NV\TdI9iW0GQR1XS
KGN MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC4T5RKSzVyPUm2MlI6KG6P NYq5SmM6W0GQR1XS
MOLT-4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTqeWRsUUN3ME25Ok44QSCwTR?= M17kPXNCVkeHUh?=
PF-382 NW\vOXhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTl4Lke5JI5O NHnlXFlUSU6JRWK=
BC-3 NGHOSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[yTWM2OD17OT6xPEBvVQ>? NWnkeGdJW0GQR1XS
KARPAS-422 NX7BTo12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPqfZhKSzVyPUGwNk4xQSCwTR?= NV3kPY1KW0GQR1XS
SBC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPETWM2OD1zMEeuO|Uhdk1? Mk[2V2FPT0WU
LC-1F MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vsOGlEPTB;MUC4MlA2KG6P NVn0fYNlW0GQR1XS
GB-1 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uwPWlEPTB;MUC5MlAzKG6P NUnWSG9GW0GQR1XS
SNB75 NGnX[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO1TWM2OD1zMUmuOlkhdk1? NHTadoxUSU6JRWK=
BB65-RCC NXXHSZJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XjcmlEPTB;MUG5Mlk{KG6P Ml:1V2FPT0WU
NCI-N87 NED0UYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfRNYtsUUN3ME2xNlEvQThibl2= MofiV2FPT0WU
IST-MEL1 NF\xfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfOTWM2OD1zMkKuN|ghdk1? MkPqV2FPT0WU
HOP-62 NXjBS3NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjlbmpxUUN3ME2xNlYvQDlibl2= NGXzO5hUSU6JRWK=
ACN NU\sS2RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF2Nj63OUBvVQ>? MX7TRW5ITVJ?
DMS-114 Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF3MD62O{BvVQ>? M3j3R3NCVkeHUh?=
MLMA Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF3OT64PEBvVQ>? MV3TRW5ITVJ?
HT-144 MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv1cJZKSzVyPUG2OU41OyCwTR?= NE\NdIVUSU6JRWK=
C2BBe1 NXvKU3NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvMTWM2OD1zNkeuO|Yhdk1? MmDnV2FPT0WU
L-428 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOyW49KSzVyPUG3O{44KG6P NYf1WIszW0GQR1XS
DU-4475 NEXIV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfpTWM2OD1zOEeuOlghdk1? MlTOV2FPT0WU
CP67-MEL M3vHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37PeWlEPTB;MUm5MlM5KG6P MlfIV2FPT0WU
MEG-01 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJyMT65OkBvVQ>? M4npR3NCVkeHUh?=
IST-SL2 NECzeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJyOD62N{BvVQ>? NFXNRWtUSU6JRWK=
ES8 NHS4dolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi4NHZKSzVyPUKyOU46PCCwTR?= MkH4V2FPT0WU
COLO-800 MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXNPYpKSzVyPUKzOU4zQCCwTR?= M3jSV3NCVkeHUh?=
MFH-ino MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DYfGlEPTB;MkO1Mlg1KG6P NIjCSYJUSU6JRWK=
OVCAR-4 NUfKSW1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfDd3BKSzVyPUKzO{4zPCCwTR?= NWqwUnNzW0GQR1XS
PSN1 M13NdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF20R4FKSzVyPUK0Nk44OSCwTR?= MVvTRW5ITVJ?
EW-12 M1XqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ2Mz6xJI5O NF\TPHlUSU6JRWK=
HCC1599 NFu4[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXMTWM2OD1{NkGuOFchdk1? NUPUS3NrW0GQR1XS
SJSA-1 MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jRV2lEPTB;MkexMlQ3KG6P MnPtV2FPT0WU
ST486 NY\6NZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXnWGUyUUN3ME2yPVYvOTRibl2= MlfjV2FPT0WU
NOMO-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H5T2lEPTB;M{CwMlIyKG6P MXjTRW5ITVJ?
MN-60 NVHDSINLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zNVWlEPTB;M{C1MlMzKG6P Mm[xV2FPT0WU
HCC1187 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzhNGxKUUN3ME2zNFcvOjVibl2= MXXTRW5ITVJ?
SW982 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED2eGZKSzVyPUOxOE44PSCwTR?= NFTRUZZUSU6JRWK=
LB647-SCLC M3vPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkftTWM2OD1|MkiuO|Ehdk1? MXXTRW5ITVJ?
HC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTN|NT61JI5O MnrhV2FPT0WU
EHEB NX;hPIJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17MSGlEPTB;M{O3MlUzKG6P NWrmUIxRW0GQR1XS
TUR NVvmd3JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLrTWM2OD1|NkOuPVUhdk1? NG[0SXhUSU6JRWK=
LU-139 MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN5OD6wNkBvVQ>? MY\TRW5ITVJ?
NB1 M4SxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TscmlEPTB;M{i0MlQ2KG6P MkPLV2FPT0WU
BB30-HNC NIDZXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTN6OD6zNkBvVQ>? Ml\aV2FPT0WU
HAL-01 NECw[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XoR2lEPTB;M{i5MlI3KG6P NHnJSHJUSU6JRWK=
K5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjJTWM2OD12MUGuN|chdk1? MXjTRW5ITVJ?
MZ2-MEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rRRmlEPTB;NEGzMlY1KG6P MmrmV2FPT0WU
RXF393 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi4eopKSzVyPUSxOk41PSCwTR?= M2nSXXNCVkeHUh?=
NCI-H1648 M1nPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDIVHVmUUN3ME20NVcvPTNibl2= NGXSWXNUSU6JRWK=
TE-12 NF71WmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzsS4xKSzVyPUSzOE4zPiCwTR?= Mk\nV2FPT0WU
EoL-1- MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnOb|hKSzVyPUSzO{46QCCwTR?= M3HpfnNCVkeHUh?=
JAR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zaW2lEPTB;NEO4MlYzKG6P Ml\ZV2FPT0WU
DSH1 M{DXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTR3OD65NUBvVQ>? MmjSV2FPT0WU
NCI-H187 NIHaSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTR4Mj64NUBvVQ>? MlzGV2FPT0WU
HCE-4 M{TZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;4TWM2OD12N{euOlYhdk1? NIfOTGJUSU6JRWK=
8-MG-BA NXy1epF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rDSmlEPTB;NUixMlUzKG6P NGjPbZpUSU6JRWK=
KLE NHrLR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\2TWM2OD13OEWuNkBvVQ>? MoHSV2FPT0WU
KNS-42 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly4TWM2OD13OE[uPFEhdk1? NWntbGRlW0GQR1XS
MSTO-211H NGexO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTZyOT63OEBvVQ>? M4fuOnNCVkeHUh?=
GDM-1 NI\1RodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HyPWlEPTB;NkG0MlA6KG6P MVjTRW5ITVJ?
TE-1 NWHKdml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jRS2lEPTB;NkS2MlEzKG6P Mm[0V2FPT0WU
BT-474 M4OyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDaTmJvUUN3ME22OFcvODZibl2= NWr1TmV6W0GQR1XS
KARPAS-45 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTZ2Nz62JI5O MnX0V2FPT0WU
MOLT-16 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZ2Nz65N{BvVQ>? MV7TRW5ITVJ?
KURAMOCHI MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LHSWlEPTB;NkW3MlUyKG6P NIDoWnNUSU6JRWK=
K-562 NYP3O4lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnDTWM2OD14NkmuOVEhdk1? NE[wc2tUSU6JRWK=
EKVX NVrSTnZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXZTWM2OD14N{KuO|Ehdk1? NV;iZ25kW0GQR1XS
GAK NYrqTWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTZ5NT6zJI5O NX7sZoVYW0GQR1XS
NCI-SNU-5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr2TWM2OD14OUCuNFEhdk1? NUPFNHpiW0GQR1XS
NCI-H2126 M{HDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX31TG9CUUN3ME23NlYvQDdibl2= NXfkXo55W0GQR1XS
CTV-1 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3jUI5iUUN3ME23OFQvQSCwTR?= NFjDXGJUSU6JRWK=
SW962 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\Ce4k3UUN3ME23OFgvPDRibl2= NG\mfmRUSU6JRWK=
MONO-MAC-6 NGfGN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTd3Nj65N{BvVQ>? NUK1epZ5W0GQR1XS
NCI-H748 M1TWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLzTWM2OD15NUiuPVkhdk1? MXfTRW5ITVJ?
NCI-H524 MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvqeXNiUUN3ME23PFAvPzNibl2= Mn3YV2FPT0WU
LS-123 NHPPe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTd7NT62PUBvVQ>? M3HZUHNCVkeHUh?=
NB7 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHoTWM2OD16MUSuNVQhdk1? NH21R3dUSU6JRWK=
LS-1034 MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTh{OD65PEBvVQ>? M1\FTnNCVkeHUh?=
TE-5 NYHueodzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXz[ZBKSzVyPUi4N{42PiCwTR?= NWXQWm1sW0GQR1XS
A704 M{LTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW5XpVKSzVyPUi5PU4yPSCwTR?= NEW5TGlUSU6JRWK=
TK10 NEnoe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX21fIVUUUN3ME25NVYvODNibl2= NYO1b3hTW0GQR1XS
NCI-H345 NVLNd41qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHjNY1KSzVyPUm0N{4zOiCwTR?= MVLTRW5ITVJ?
CGTH-W-1 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrDTWM2OD17NEiuNVMhdk1? NILyNG5USU6JRWK=
NCI-H510A M4rofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TTRWlEPTB;OUi1MlEzKG6P NVrROVMyW0GQR1XS
NCI-H1963 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HGU2lEPTB;MT6wN|I6OiEQvF2= MYLTRW5ITVJ?
SCC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMEO0NVQh|ryP NGjHRnBUSU6JRWK=
EW-11 NFPSPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3THb2lEPTB;MT6wPFc1OyEQvF2= M3i0dHNCVkeHUh?=
CPC-N NHHHfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFwMEi4JO69VQ>? MUHTRW5ITVJ?
NCI-H1417 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwMUKyOkDPxE1? NYHRdFZlW0GQR1XS
DG-75 NXXUUIx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37xVmlEPTB;MT6xOlI5PSEQvF2= NXnyWWt1W0GQR1XS
HD-MY-Z NYnuXnRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLN[Ig3UUN3ME2xMlE3PDF4IN88US=> MWTTRW5ITVJ?
ATN-1 MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPwfZVKSzVyPUGuNlYzODlizszN MkXLV2FPT0WU
KM-H2 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLjUFhEUUN3ME2xMlI3PDB6IN88US=> M3jWWXNCVkeHUh?=
NCI-H2081 M4OzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;IRmlEPTB;MT6yOlY{PyEQvF2= NXnkeY1{W0GQR1XS
HL-60 M{\zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;SToQ4UUN3ME2xMlI3QTV7IN88US=> MlXJV2FPT0WU
DB M3nlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjZTWM2OD1zLkK3NlQzKM7:TR?= NF\2S|RUSU6JRWK=
NCI-H1522 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\kfXdkUUN3ME2xMlI5QDh5IN88US=> M2P5dXNCVkeHUh?=
AM-38 M2j0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7yTWM2OD1zLkOwO|Ih|ryP NGHodpJUSU6JRWK=
NCI-H446 M3nnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHJTWM2OD1zLkOyNVIyKM7:TR?= NXfhSJVXW0GQR1XS
SU-DHL-1 NFO3WGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwM{K4NFEh|ryP M2i3cXNCVkeHUh?=
NH-12 M3;KU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvOTWM2OD1zLkO2N|c1KM7:TR?= M33kU3NCVkeHUh?=
DMS-79 M4HZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf6SHJKSzVyPUGuN|Y5PjZizszN MmDvV2FPT0WU
NCI-H716 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvkOnNKSzVyPUGuN|g6QDZizszN MnfNV2FPT0WU
ML-2 NFTBTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjHO2g1UUN3ME2xMlQyPTJ7IN88US=> MoTMV2FPT0WU
NB10 MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPBZ41KSzVyPUGuOFY3OzJizszN M1;UdHNCVkeHUh?=
ONS-76 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi3ToNUUUN3ME2xMlU{PTZ7IN88US=> NX3Vc2dvW0GQR1XS
LOUCY NIjsUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwNUS2OVch|ryP NUL6eIxRW0GQR1XS
SCLC-21H MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwNUi1PFIh|ryP NUPLcllTW0GQR1XS
TGW M3LSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PNfWlEPTB;MT62N|k4PSEQvF2= NV;OW|F7W0GQR1XS
LXF-289 NFTocpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfJO2dKSzVyPUGuO|MzPjhizszN MYXTRW5ITVJ?
BB49-HNC NUP5OI83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ez[WlEPTB;MT63N|U5PiEQvF2= MYrTRW5ITVJ?
NCI-H747 M3LnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7SNWc4UUN3ME2xMlc2OzR4IN88US=> MXnTRW5ITVJ?
LU-165 NH3iPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXBfG5tUUN3ME2xMlg1QTh4IN88US=> Ml[3V2FPT0WU
OMC-1 NULNbW9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PvTWlEPTB;MT65OVA3PiEQvF2= MmnnV2FPT0WU
RCC10RGB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrlT4dKSzVyPUGuPVU5OTdizszN M{DlcHNCVkeHUh?=
SW684 NIPmSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[zNnpSUUN3ME2xMlk3ODl7IN88US=> NFPkS3RUSU6JRWK=
TE-8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPKTWM2OD1{LkC1OVU6KM7:TR?= M1LITXNCVkeHUh?=
SK-N-DZ MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLGTWM2OD1{LkGzNlc1KM7:TR?= NEXC[4dUSU6JRWK=
EVSA-T MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XSUWlEPTB;Mj6xO|MyPSEQvF2= NYLMNmRMW0GQR1XS
KASUMI-1 Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLmTWM2OD1{LkG4PFE2KM7:TR?= M1TtVHNCVkeHUh?=
NKM-1 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwMkW0O|Ih|ryP NUPsboRmW0GQR1XS
CAL-148 NVvzdnR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\aVlY{UUN3ME2yMlM{PjF2IN88US=> NEnXV2RUSU6JRWK=
NCI-H64 M1zM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJwM{SyN|Ih|ryP NXvaW3ZtW0GQR1XS
KNS-81-FD NFHubYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e1WGlEPTB;Mj6zOlYzKM7:TR?= M3LDZXNCVkeHUh?=
KM12 NFfW[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGWwTnJKSzVyPUKuOFA5OzlizszN MnS5V2FPT0WU
SW954 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T1UGlEPTB;Mj60O|c4QSEQvF2= MkfxV2FPT0WU
NCI-H1395 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjCPYkyUUN3ME2yMlUzPjR3IN88US=> MV3TRW5ITVJ?
DJM-1 NVrCRlBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7KWGxKSzVyPUKuOlA3OyEQvF2= MX7TRW5ITVJ?
COLO-668 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SzUWlEPTB;Mj64NlY6PSEQvF2= MnvHV2FPT0WU
NCI-H1436 NV7hPYJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzNTWM2OD1{Lki1OlE2KM7:TR?= MVfTRW5ITVJ?
LB2241-RCC NVjKNZJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJwOE[4N|kh|ryP MV;TRW5ITVJ?
GT3TKB MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrTTWM2OD1{Lki5NFU2KM7:TR?= NEX5R4VUSU6JRWK=
COLO-824 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJwOEm3Olgh|ryP NVvv[HBOW0GQR1XS
ES1 NX\DWHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLJTWM2OD1{Lki5PFc6KM7:TR?= NEHLT|NUSU6JRWK=
LB771-HNC NWnWNlJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Lzc2lEPTB;Mj65NFk1PiEQvF2= MUfTRW5ITVJ?
GI-ME-N MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq3Oo1tUUN3ME2zMlAxQTB2IN88US=> NV;KO4VpW0GQR1XS
NALM-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNwMEC5N|Mh|ryP MV\TRW5ITVJ?
LU-134-A NHXhZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XxUGlEPTB;Mz6wOVQzPSEQvF2= MVrTRW5ITVJ?
DMS-153 M2js[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNwMEW4NlQh|ryP MWLTRW5ITVJ?
MZ1-PC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTNwMEmwO|gh|ryP M33obXNCVkeHUh?=
NCI-H1155 NInaSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqzcZdOUUN3ME2zMlEyPjFizszN NXfkVWhJW0GQR1XS
CAS-1 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X0ZWlEPTB;Mz6xN|cxPyEQvF2= M1GxeHNCVkeHUh?=
D-502MG NUnYXGF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm1TWM2OD1|LkG0N|kh|ryP MU\TRW5ITVJ?
NCI-H2141 Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPoZ2pKSzVyPUOuNVc1PTJizszN M3GycXNCVkeHUh?=
NB6 M3\seGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnnWJBKSzVyPUOuNVgzPTlizszN MYLTRW5ITVJ?
NCCIT NUnVVlRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofhTWM2OD1|LkKxPFA6KM7:TR?= MXXTRW5ITVJ?
NB69 NUnabWQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe1W5VKSzVyPUOuN|E5QTFizszN NVTJNm5EW0GQR1XS
JVM-2 M4LTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH60VndKSzVyPUOuN|Y1OzNizszN MVTTRW5ITVJ?
K052 NFvTXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFWzfIlKSzVyPUOuN|c6PjhizszN M{XvdXNCVkeHUh?=
HCC2157 NG\ZRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;FTWM2OD1|LkWzNlI5KM7:TR?= MmnvV2FPT0WU
KMOE-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPWTWM2OD1|LkW0NlQzKM7:TR?= M{XF[nNCVkeHUh?=
SF268 M3;zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLRTWM2OD1|LkexOVU1KM7:TR?= M3zIWHNCVkeHUh?=
CHP-126 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLvU|QyUUN3ME2zMlc3PDV6IN88US=> NHT4epdUSU6JRWK=
CP66-MEL MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNwN{mwPVQh|ryP NX\ueYJkW0GQR1XS
NCI-H69 NEPnWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:2TWM2OD12LkCxPVM3KM7:TR?= M3:4O3NCVkeHUh?=
A253 NXTL[IpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTRwMEKxNFEh|ryP NVPkXYlIW0GQR1XS
NB14 M4rrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;GWWlEPTB;ND6xNFQ4QSEQvF2= NVPYZ3VVW0GQR1XS
NCI-H1694 NELMS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\CTWM2OD12LkGzNVEzKM7:TR?= MkLvV2FPT0WU
NCI-H2196 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV24SYRRUUN3ME20MlE4OTZ7IN88US=> MlvxV2FPT0WU
TE-9 NILLN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;aTWZTUUN3ME20MlE4PTh{IN88US=> MljPV2FPT0WU
D-283MED M4W3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnuOnhKSzVyPUSuNVg5PCEQvF2= NVnZVGtQW0GQR1XS
OCI-AML2 M4\wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DVS2lEPTB;ND6xPVQ5QSEQvF2= MlPzV2FPT0WU
D-263MG M2PJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELkeIRKSzVyPUSuNlI6PjFizszN MkHFV2FPT0WU
MPP-89 NI\pclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTRwMkezNFQh|ryP MW\TRW5ITVJ?
LAMA-84 NIDuepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL1TWM2OD12LkOwOFIyKM7:TR?= MVPTRW5ITVJ?
LB373-MEL-D MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjwTWM2OD12LkO2O|g6KM7:TR?= NWTvVWZLW0GQR1XS
UACC-257 M3zsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnxS4xKSzVyPUSuN|k2OzRizszN NFrmfFRUSU6JRWK=
MC-CAR MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jIdWlEPTB;ND60N|k6KM7:TR?= MYnTRW5ITVJ?
COLO-320-HSR MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDYZpdKSzVyPUSuOFQ1OjdizszN M3H4VXNCVkeHUh?=
P30-OHK NID6fldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzJTWM2OD12Lk[2OVgyKM7:TR?= M2jQN3NCVkeHUh?=
UACC-812 NV\PeZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3Ue2ZKSzVyPUSuOlkyPjFizszN NHnPUmRUSU6JRWK=
CTB-1 NUDNXnF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrjTWM2OD12LkexOVU2KM7:TR?= M{HyZ3NCVkeHUh?=
ALL-PO NUfmcYhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL5TWM2OD12Lki0NFc4KM7:TR?= NYnnWZR4W0GQR1XS
SK-MEL-2 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTRwOE[5OVUh|ryP M3vwcXNCVkeHUh?=
TC-YIK MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTUU5RKSzVyPUSuPVc6PDJizszN M4PpeHNCVkeHUh?=
NCI-H1882 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;zWmlEPTB;NT6wNlAxOSEQvF2= MlntV2FPT0WU
MHH-CALL-2 M4rW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nRS2lEPTB;NT6wOVA1OiEQvF2= M1yzfnNCVkeHUh?=
U-87-MG MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jjOWlEPTB;NT6wPVQ3PiEQvF2= NUXDOZc3W0GQR1XS
NCI-H1092 NFPSbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3wXJhKSzVyPUWuNlY2PTVizszN Mn:2V2FPT0WU
TE-441-T M2rkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTVwMke4NkDPxE1? M2TVdnNCVkeHUh?=
SK-MEL-1 NULBPZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTVwMkmwOFQh|ryP MUHTRW5ITVJ?
EW-22 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn33TWM2OD13LkK5OFY3KM7:TR?= MV3TRW5ITVJ?
MZ7-mel MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjUNYxSUUN3ME21MlQxPjlzIN88US=> NWfuUIhRW0GQR1XS
LP-1 NETmdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTVwNEGyPVEh|ryP MmnZV2FPT0WU
NCI-SNU-16 NUTTdI9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXkc3BKSzVyPUWuOlQxPzRizszN MoizV2FPT0WU
LU-65 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnhWmVoUUN3ME21Mlc3Ozd|IN88US=> M2DXWHNCVkeHUh?=
CW-2 NFnYOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTVwOEW5OVkh|ryP NGL6bVVUSU6JRWK=
WSU-NHL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHHcJlKSzVyPUWuPVUyPzRizszN MmnPV2FPT0WU
IST-MES1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEi2UY1KSzVyPUWuPVU1PDNizszN NFn5b|FUSU6JRWK=
U-266 NHzBPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy2XJJ3UUN3ME21Mlk5OjB{IN88US=> MlXxV2FPT0WU
TALL-1 NXnwT4tVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfNNmFYUUN3ME22MlE1Pjh6IN88US=> MonZV2FPT0WU
Calu-6 NHv3dWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTufmRrUUN3ME22MlE2OzF4IN88US=> NE\RRVNUSU6JRWK=
MMAC-SF M2PCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTxUo5KSzVyPU[uNVg2PTZizszN M{PUeXNCVkeHUh?=
NCI-H82 NV3TfnN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn65TWM2OD14LkKwOFg6KM7:TR?= NHjnbXJUSU6JRWK=
RS4-11 M2rJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHOOFF3UUN3ME22MlI2QDl5IN88US=> NVvGZ2ZbW0GQR1XS
SNU-C2B NGL0TmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SyPGlEPTB;Nj60NFk3QSEQvF2= MlGwV2FPT0WU
BOKU MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe0V5NrUUN3ME22MlQ4PTl5IN88US=> NELqUZBUSU6JRWK=
C8166 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjvcHBCUUN3ME22MlU2QTF{IN88US=> NHnBVpJUSU6JRWK=
D-247MG Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH6TWM2OD15LkC0N|Q4KM7:TR?= MVnTRW5ITVJ?
EW-18 NF3tT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTdwMEeyPVIh|ryP NVXtT3l5W0GQR1XS
KG-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[wO|RKSzVyPUeuOlI4OzhizszN NGLRPI9USU6JRWK=
REH MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;HTWM2OD15Lk[4NVA6KM7:TR?= NGLBU2JUSU6JRWK=
U-698-M NX;pcGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r1dmlEPTB;Nz64OFMyPSEQvF2= NVfob4dJW0GQR1XS
KP-N-RT-BM-1 M3j3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrDVXlXUUN3ME23Mlk{ODJ7IN88US=> NX\pfoJDW0GQR1XS
MS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTdwOU[wOFEh|ryP MmnKV2FPT0WU
SNU-C1 NXvqWXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTdwOUixPVIh|ryP Mn7LV2FPT0WU
SK-MM-2 NHLtcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vUZ2lEPTB;OD6yOlA3PSEQvF2= NVLtZXg{W0GQR1XS
LAN-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHF[4RKSzVyPUiuN|AxODFizszN M2XwNHNCVkeHUh?=
NEC8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX61UZV2UUN3ME24MlMxPjlzIN88US=> M17aO3NCVkeHUh?=
NCI-H1770 NWO3T2czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjTfm1KSzVyPUiuN|gxODJizszN NInRUItUSU6JRWK=
D-336MG M1rwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonOTWM2OD16LkSwNVE3KM7:TR?= MUHTRW5ITVJ?
COLO-829 M{DaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jv[GlEPTB;OD60PFg4QSEQvF2= M2jhWHNCVkeHUh?=
LS-513 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7sTWM2OD16LkW5OVk6KM7:TR?= M{nBRXNCVkeHUh?=
YT MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRThwNkK0Nlch|ryP MkXnV2FPT0WU
EW-24 NEPVS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRThwN{[1OEDPxE1? NIHFSYpUSU6JRWK=
IST-SL1 M2PGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRThwOE[1OFMh|ryP M3HJeXNCVkeHUh?=
CA46 M{Hre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRThwOUWwPVgh|ryP MmnkV2FPT0WU
NCI-H1838 M{TTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRThwOUi2NFIh|ryP MUjTRW5ITVJ?
NCI-H719 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTlwMkWyO|kh|ryP NYfQem1TW0GQR1XS
HCE-T MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTlwM{C4OVEh|ryP M2PBPHNCVkeHUh?=
A498 NFTRbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTlwM{[xNlQh|ryP MY\TRW5ITVJ?
LB831-BLC M3\wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfhXoFWUUN3ME25Mlc3PTJzIN88US=> MXfTRW5ITVJ?
SKM-1 M{Dxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3mTWM2OD17Lki1PVY{KM7:TR?= MknhV2FPT0WU
THP-1 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\5TVFmUUN3ME25Mlk3QTF6IN88US=> NWfTT4dlW0GQR1XS
SHP-77 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfTN29lUUN3ME2xNE41ODdizszN NFzsSIlUSU6JRWK=
EW-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH1RoJPUUN3ME2xNE43Ojh7IN88US=> M{jGS3NCVkeHUh?=
KY821 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTF[pJKSzVyPUGwMlc3OyEQvF2= MoniV2FPT0WU
NCI-SNU-1 MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFzLkCyNVch|ryP MkjQV2FPT0WU
HCC2218 NVzONlc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFzLkO5PFYh|ryP Mlq0V2FPT0WU
IM-9 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X3V2lEPTB;MUGuOVExPiEQvF2= MYjTRW5ITVJ?
NCI-H889 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLuTWM2OD1zMT61N|E{KM7:TR?= MW\TRW5ITVJ?
HDLM-2 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT0TWM2OD1zMj60NVU6KM7:TR?= MUfTRW5ITVJ?
LB2518-MEL NXe1c2QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnifYJKSzVyPUGyMlY5OTVizszN M1TsV3NCVkeHUh?=
NCI-H23 NGLabItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF|LkK0NlUh|ryP M{[1WXNCVkeHUh?=
NB17 M1n3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPPXVI6UUN3ME2xN{41PTd7IN88US=> MVXTRW5ITVJ?
NCI-H322M M{POW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFriNWtKSzVyPUG0MlQxPjhizszN M4rNTXNCVkeHUh?=
SUP-T1 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjxTWM2OD1zND60NVMh|ryP MXnTRW5ITVJ?
ES3 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnZTWM2OD1zNT6wO|A{KM7:TR?= M1PNWXNCVkeHUh?=
ES5 M4TUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nFWmlEPTB;MUWuNFc5PyEQvF2= NXvy[WRiW0GQR1XS
NCI-H1650 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF3LkS5O|kh|ryP NI\Re3lUSU6JRWK=
NCI-H226 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO5SI9tUUN3ME2xOU45PzZ6IN88US=> Mn7QV2FPT0WU
COR-L88 NIK3cYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLDdpQxUUN3ME2xOk4{OTRizszN NIq4WWtUSU6JRWK=
SCC-15 NEK0SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXXTWM2OD1zNj6zPFY6KM7:TR?= M3j4WHNCVkeHUh?=
GOTO MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoraTWM2OD1zNj60O|k{KM7:TR?= NFyxeoZUSU6JRWK=
SIMA MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHOTWM2OD1zNj60PFAzKM7:TR?= MkO2V2FPT0WU
NCI-H1299 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7qeYVnUUN3ME2xO{4yPTlzIN88US=> Ml;XV2FPT0WU
NCI-H1581 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfzUY9KSzVyPUG3MlQzOTlizszN NH2wN5hUSU6JRWK=
MHH-NB-11 NXTNXGtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jTR2lEPTB;MUeuPVY5OyEQvF2= MoLEV2FPT0WU
MFM-223 NWPxXpptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXTdFVPUUN3ME2xPE4xPTN6IN88US=> NWjON|FiW0GQR1XS
ES7 NUXaTINnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy4TGpKSzVyPUG4MlU1OzFizszN NGPlRm9USU6JRWK=
JVM-3 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3MXIZ6UUN3ME2xPE44OTdizszN NXiyc3h4W0GQR1XS
RL MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK3Z2Y3UUN3ME2yNE4{QDhizszN MVHTRW5ITVJ?
EC-GI-10 NXm5dGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJzLkKwOFEh|ryP MWXTRW5ITVJ?
LNCaP-Clone-FGC NGXSRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJzLk[3Olgh|ryP MkjDV2FPT0WU
IMR-5 MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfrNm5zUUN3ME2yNU45PDl2IN88US=> NYrXXmV{W0GQR1XS
KP-N-YS Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHmNHNsUUN3ME2yNU45PzVizszN NHjyd4pUSU6JRWK=
Mo-T MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2joWmlEPTB;MkKuNlE5PSEQvF2= MmOyV2FPT0WU
NCI-H128 NEjYcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LyRWlEPTB;MkOuOVg2OyEQvF2= NFTCS2NUSU6JRWK=
RH-1 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO1cFlkUUN3ME2yN{44QDZ4IN88US=> NVL3SG5YW0GQR1XS
NCI-H2171 M2ryTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjNUldlUUN3ME2yOE4zPDh3IN88US=> M4iwWnNCVkeHUh?=
RPMI-8866 NHztNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\iTWM2OD1{Nj63OFIh|ryP M3PU[nNCVkeHUh?=
SK-N-FI MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfPemh6UUN3ME2yO{4{QDFzIN88US=> M{O2NHNCVkeHUh?=
LOXIMVI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj5enNKSzVyPUK3MlgxPTFizszN NWrwcpR[W0GQR1XS
P31-FUJ NYXDSHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXryfWN6UUN3ME2zNU42Ozd2IN88US=> MX;TRW5ITVJ?
KMS-12-PE NFO5OmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS0UYFkUUN3ME20PU42OzB{IN88US=> Mlm3V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ